Interleukin-6 polymorphisms and hematologic malignancy: a re-appraisal of evidence from genetic association studies.
BACKGROUND
Interleukin-6 (IL-6) is implicated in the pathophysiology of hematologic neoplasia.


OBJECTIVE
To review the role of IL-6 single nucleotide polymorphisms (SNPs) in hematologic neoplasia.


METHODS
PubMed and EMBASE search of genetic association studies. Effects were summarized using the model-free generalized odds ratio (ORG), and the mode of inheritance was estimated for significant associations.


RESULTS
Seventeen articles provided data on 20 distinct SNPs. The IL-6 receptor rs8192284 was associated with an increased risk of hematologic malignancy (combined ORG 1.42, 95%CI 1.03-1.96), including multiple myeloma (ORG 1.39, 95%CI 0.99-1.95). The IL-6 promoter rs1800795 conferred protection against young adult Hodgkin's disease (ORG 0.68, 95%CI 0.48-0.95). Significant single-study effects for four other SNPs-disease associations were estimated. The IL-6 promoter rs1800795 and rs1800797 were not associated with overall susceptibility to non-Hodgkin's lymphomas.


CONCLUSIONS
There is accumulating evidence that the IL-6 promoter, receptor and signal transducer SNPs can modify disease susceptibility.
Division of Infectious Diseases, Rhode Island Hospital , Providence, RI , USA .
Panayiotis D
PD
Ziakas
Petros
P
Karsaliakos
Michael L
ML
Prodromou
Eleftherios
E
Mylonakis
D016022:Case-Control Studies; D056726:Genetic Association Studies; D020022:Genetic Predisposition to Disease; D006801:Humans; D015850:Interleukin-6 / Q000235:genetics*; D008223:Lymphoma / Q000235:genetics*; D009101:Multiple Myeloma / Q000235:genetics*; D020641:Polymorphism, Single Nucleotide; D011401:Promoter Regions, Genetic; D012306:Risk
C508600:IL6 protein, human; D015850:Interleukin-6